FDA-NDA220073
Document details
Summary
Eliquis (apixaban) has received approval for a new oral suspension dosage form under NDA220073, expanding access for patients unable to swallow tablets—likely pediatric or dysphagic populations. As anEliquis oral suspension approved; oral route confirms Part D pathway.
Affected specialty
Cardiology alerts →Source document
http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220073s000lbl.pdfCLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA202155 · Cardiology
Eliquis (apixaban) is an oral anticoagulant approved as a tablet (including a tablet for suspension formulation), which routes it through Medicare Part D for outpatient prescription coverage. As an or
View alertPolicy FDA-NDA022434 · Cardiology
Argatroban in sodium chloride is an injectable medication that will likely receive a J-code for billing purposes under Medicare Part B. As an intravenous drug, it may also qualify for pass-through pay
View alertPolicy LCD-L40255 (Notice Ends 06/20/2026) · Cardiology
This final LCD from Noridian (JE/JF) governs coverage of temporary nontherapeutic ambulatory cardiac monitoring devices across 15 western states, effective June 21, 2026. It defines coverage criteria
View alertPolicy LCD-L40257 (Notice Ends 06/27/2026) · Cardiology
Palmetto GBA has finalized LCD L40257 governing coverage of temporary nontherapeutic ambulatory cardiac monitoring devices across seven southeastern states, effective June 28, 2026. This LCD establish
View alert